Inhibrx Biosciences公布了其在软骨肉瘤的Ozekibart (Inbrx-109)注册试验中的积极顶线结果,并提供了对结直肠癌和尤文肉瘤扩展队列的最新进展

美股速递
Oct 24, 2025

Inhibrx Biosciences公布了其在软骨肉瘤的Ozekibart (Inbrx-109)注册试验中的积极顶线结果,并提供了对结直肠癌和尤文肉瘤扩展队列的最新进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10